[HTML][HTML] Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the …

J Goedegebuur, D Abbel, S Accassat… - Thrombosis research, 2023 - Elsevier
Background Even though antithrombotic therapy has probably little or even negative effects
on the well-being of people with cancer during their last year of life, deprescribing …

Thrombosis and bleeding in hematological malignancy

TF Wang, A Leader, KM Sanfilippo - Best Practice & Research Clinical …, 2022 - Elsevier
Venous (VTE) and arterial (ATE) thromboemboli are a leading cause of morbidity and
mortality in patients with cancer. Patients with hematological malignancies are at an …

Prevalence of cancer in patients with venous thromboembolism: a retrospective nationwide case-control study in Sweden

K Glise Sandblad, PO Hansson… - Clinical and Applied …, 2023 - journals.sagepub.com
Cancer is a risk factor for venous thromboembolism (VTE). We aimed to define sex-specific
risk of preceding cancer in patients with a first-time VTE by conducting a nationwide …

The year in cardiovascular medicine 2021: cardio-oncology

J Herrmann, T López-Fernández… - European heart …, 2022 - academic.oup.com
Publications in cardio-oncology have increased exponentially over the past two decades.
The Year in Cardiovascular Medicine: Cardio-Oncology 2020–21 covers the most recent …

[HTML][HTML] Transgender medicine and risk of venous thromboembolism

CC Van Bunderen, J Leentjens… - …, 2022 - thieme-connect.com
Gender dysphoria refers to psychological distress that results from an incongruence
between gender identity and sex assigned at birth. Administration of sex hormones is most …

Profile of solid tumor patients complicated with venous thromboembolism: a 10-year retrospective cross-sectional study based on 1482 cases

H Li, Y Tian, H Niu, L He, G Cao… - Clinical and Applied …, 2023 - journals.sagepub.com
The aim of this single-centre 10-year retrospective observational study was to evaluate the
profile of Chinese cancerous patients complicated with venous thromboembolism (VTE) …

Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study

S Nopp, F Moik, S Kraler, C Englisch… - Journal of Thrombosis …, 2023 - Elsevier
Background Patients with cancer are at increased risk of venous thromboembolism (VTE)
and arterial thromboembolic/thrombotic events (ATEs). Growth differentiation factor-15 (GDF …

Associations Between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

H Li, H Li, L Tang, H Niu, L He… - Clinical and Applied …, 2023 - journals.sagepub.com
This study aims to summarize the available data and determine if the presence of venous
thromboembolism (VTE) immune-related adverse event (irAE) in patients with immune …

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

C Englisch, F Moik, J Thaler, S Koder… - …, 2023 - thieme-connect.com
Method Total TFPI antigen levels at study inclusion (Imunbind total TFPI ELISA kit, American
Diagnostica Inc., USA) were measured in patients included in the Vienna Cancer and …

[HTML][HTML] Machine learning to calculate heparin dose in COVID-19 patients with active cancer

E Imbalzano, L Orlando, A Sciacqua, G Nato… - Journal of Clinical …, 2021 - mdpi.com
To realize a machine learning (ML) model to estimate the dose of low molecular weight
heparin to be administered, preventing thromboembolism events in COVID-19 patients with …